scholarly journals Molecular fingerprinting of Helicobacter pylori strains from duodenal ulcer patients

2003 ◽  
Vol 36 (4) ◽  
pp. 222-226 ◽  
Author(s):  
L. Cellini ◽  
E. Di Campli ◽  
M. Di Candia ◽  
L. Marzio
Keyword(s):  
Duodenal Ulcer ◽  
Helicobacter Pylori ◽  
Molecular Fingerprinting

scholarly journals Gastric Acid-Related Diseases: Focus on Esomeprazole

2010 ◽  
Vol 2 ◽  
pp. CMT.S4500
Author(s):  
B. Al-Judaibi ◽  
N. Chande ◽  
G.K. Dresser ◽  
N. Sultan ◽  
J.C. Gregor
Keyword(s):  
Duodenal Ulcer ◽  
Helicobacter Pylori ◽  
Symptom Relief ◽  
Competitive Inhibitor ◽  
Gastric Ph ◽  
Disease Treatment ◽  
Ulcer Disease ◽  
Zollinger Ellison Syndrome ◽  
Prevention And Treatment ◽  
Inflammatory Drugs

Esomeprazole (S-omeprazole) is a single optical enantiomer proton-pump inhibitor (PPI) approved for the management of gastro-oesophageal reflux disease, the prevention and treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAID) associated gastric ulcer disease, treatment of duodenal ulcer disease associated with Helicobacter pylori infection, and the treatment of Zollinger-Ellison syndrome. Esomeprazole has been shown to be safe and effective during pregnancy and was introduced to the market in 2001. PPI therapy may interact with clopidogrel by cytocrome 2C19. Clopidogrel is a prodrug which is partially activated by cytochrome 2C19 and esomeprazole is a competitive inhibitor of 2C19. Esomeprazole is more effective than other PPIs in controlling esophageal and gastric pH, but efficacy in symptom relief is less clear.

A preliminary report on Helicobacter pylori and antral gastrin concentration in patients with duodenal ulcer

1994 ◽  
Vol 55 (1) ◽  
pp. 1-7 ◽  
Author(s):  
F. Vianello ◽  
B. Germanà ◽  
M. Plebani ◽  
P. Dotto ◽  
T. Del Bianco ◽  
...  
Keyword(s):  
Duodenal Ulcer ◽  
Helicobacter Pylori ◽  
Preliminary Report
Sign in / Sign up

Export Citation Format

Share Document